Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
Launched by VISTAKON PHARMACEUTICALS · Sep 20, 2005
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy normal volunteers age \>=3 years with normal ocular health and a best-corrected logMAR score of 0.3 or better
- • -
- Exclusion Criteria:
- • intraocular surgery and/or ocular surgical intervention within last 3 months, refractive surgery within last 6 months, active ocular disorder other than refractive disorders, breastfeeding women, pregnant female \< 18 years of age -
About Vistakon Pharmaceuticals
Vistakon Pharmaceuticals, a subsidiary of Johnson & Johnson Vision, is a leading innovator in the development of advanced contact lens technologies and ocular health solutions. Committed to enhancing vision and eye care, Vistakon leverages cutting-edge research and clinical trials to deliver high-quality products that meet the diverse needs of eye care professionals and their patients. With a strong focus on safety, efficacy, and patient satisfaction, Vistakon plays a vital role in shaping the future of vision correction and maintaining optimal ocular health worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Las Vegas, Nevada, United States
Charlotte, North Carolina, United States
Phoenix, Arizona, United States
Bel Air, Maryland, United States
North Andover, Massachusetts, United States
Patients applied
Trial Officials
Jack V Greiner, OD, DO, PhD
Principal Investigator
Ophthalmic Research Associates, North Andover, MA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials